ALK B ALK-ABELLO A/S

ALK upgrades its full-year financial outlook

ALK upgrades its full-year financial outlook

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that based on a strong sales momentum and the outlook for the remainder of the year, ALK has upgraded its full-year outlook. As a result:

  • Revenue is now expected to grow 10-13% in local currencies (previously: 8-12%).
  • EBITDA is now expected to increase to DKK 675-750 million (previously: 625-725).

ALK will publish its Q2 performance in connection with the six-month interim report on 11 August 2022.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Jeppe Ilkjær, mobile

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at





Attachment



EN
04/08/2022

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
02/17/26 February 17, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20...

Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20. februar 2026 ALK (ALKB:DC / OMX: ALK B) offentliggør sin årsrapport for 2025 om morgenen fredag den 20. februar 2026. ALK afholder senere samme dag kl. 13.30 (CET) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef.  Live audio-webcast Mødet audiocastes live på , hvor genafspilning af præsentationen også vil vær...

February 13, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s annual report 2025 on Friday, ...

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026 ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.  Live audio webcast The meeting will be audio webcasted live and be availab...

February 13, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri a...

ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri anafylaksibehandling til børn Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at Det Europæiske Lægemiddelagenturs komite for godkendelse af medicin til mennesker (Committee for Medicinal Products for Human Use, ‘CHMP’) har vedtaget at anbefale en godkendelse af adrenalinnæsesprayen EURneffy® 1 mg (varemærket for neffy® i EU)  til akutbehandling af allergiske reaktioner (anafylaksi) forårsaget af insektstik eller -bid, fødevarer, medicinske produkter og andre allergener samt idiopatisk eller træningsinducer...

January 29, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free...

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of the marketing authorisation for EURneffy® (the trade name for neffy® in the EU) to include a 1 mg nasal adrenaline spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as wel...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch